BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025

Core Insights - BioVersys AG has made significant clinical and regulatory advancements across its pipeline, particularly with its lead candidates BV100 and alpibectir, positioning the company favorably in the biopharmaceutical market [4][5]. Financial Performance - For the year ended December 31, 2025, BioVersys reported total operating income of CHF 3.3 million, an increase from CHF 1.2 million in 2024 [16]. - The company incurred an operating loss of CHF 20 million in 2025, compared to CHF 18.7 million in 2024, with R&D expenses constituting approximately 71% of total operating expenses [17]. - The net loss for 2025 was CHF 21.8 million, up from CHF 18.7 million in 2024, while cash and cash equivalents increased to CHF 82.5 million from CHF 26.6 million [18][20]. Pipeline Developments - BV100 has initiated a global Phase 3 trial (RIV-TARGET) for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by carbapenem-resistant Acinetobacter baumannii, with FDA approval for its IND [6][7]. - A Phase 2b trial (RIV-CARE) for BV100 is set to begin in H1 2026, supported by the ADVANCE-ID clinical trial network [8]. - Alpibectir is progressing through a Phase 2 clinical trial for pulmonary tuberculosis, with the first patient visit reported in March 2026 [10][12]. Strategic Partnerships - BioVersys has entered into a research collaboration with Shionogi for its BV500 program, which includes potential milestone payments of up to CHF 479 million [14][15]. - The partnership with ADVANCE-ID, financially supported by Wellcome, enhances the company's clinical trial capabilities [22]. Market Position and Outlook - The company is well-positioned to benefit from recent policy changes and reimbursement reforms for novel antibiotics, particularly in Europe [5]. - BioVersys anticipates a total operating loss in the range of CHF 40.0 to CHF 45.0 million for the full year 2026, reflecting ongoing investments in its pipeline [26][27].